Lineage Cell Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $2,868 | $3,779 | $1,408 | $1,444 |
Gross Profit | 2,714 | 3,741 | 1,364 | 1,171 |
EBITDA | -4,959 | -3,699 | -5,725 | -6,486 |
EBIT | -5,110 | -3,840 | -5,867 | -6,661 |
Net Income | -3,273 | -3,034 | -5,760 | -6,542 |
Net Change In Cash | 2,868 | 3,779 | 1,408 | 1,444 |
Free Cash Flow | -6,711 | -5,699 | -5,226 | -5,821 |
Cash | 45,789 | 27,750 | 29,622 | 43,576 |
Basic Shares | 200,193 | 188,835 | 188,813 | 182,909 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $9,499 | $8,945 | $14,703 | $3,896 |
Gross Profit | 9,165 | 8,274 | 13,975 | 2,470 |
EBITDA | -21,478 | -24,041 | -21,793 | -48,338 |
EBIT | -24,733 | -22,520 | -49,225 | |
Net Income | -18,609 | -21,486 | -26,353 | -38,564 |
Net Change In Cash | 9,499 | 8,945 | 14,703 | 3,896 |
Cost of Revenue | -43,468 | 23,114 | ||
Free Cash Flow | -23,092 | -29,240 | 646 | -23,915 |
Cash | 45,789 | 35,442 | 11,355 | 55,742 |
Basic Shares | 200,193 | 172,663 | 169,792 | 164,502 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.01 |
2024-09-30 | -$0.02 |
2024-06-30 | -$0.03 |
2024-03-31 | -$0.04 |
